Neurocrine Biosciences (NBIX) News Today → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free NBIX Stock Alerts $139.83 -3.20 (-2.24%) (As of 05/2/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $164.00 by Analysts at Canaccord Genuity Groupmarketbeat.com - May 2 at 4:28 PMSummit Global Investments Acquires 10,696 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)marketbeat.com - May 2 at 4:08 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcriptmsn.com - May 2 at 1:53 PMNeurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectationsfinance.yahoo.com - May 2 at 1:53 PMBuy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipelinemarkets.businessinsider.com - May 2 at 8:53 AMNeurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...finance.yahoo.com - May 2 at 8:53 AMQ1 2024 Neurocrine Biosciences Inc Earnings Call Transcriptgurufocus.com - May 2 at 1:02 AMNeurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancementsfinance.yahoo.com - May 1 at 11:17 PMNeurocrine Biosciences Inc Q1 Earnings Summarynasdaq.com - May 1 at 1:16 PMNeurocrine’s Hold Rating Affirmed Amid Earnings Shortfall and Steady Sales Outlookmarkets.businessinsider.com - May 1 at 1:16 PMCracking The Code: Understanding Analyst Reviews For Neurocrine Biosciencesmarkets.businessinsider.com - May 1 at 1:16 PMWhy Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotechfinance.yahoo.com - May 1 at 1:16 PMNBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024investorplace.com - May 1 at 1:02 PMNeedham & Company LLC Reiterates "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX)marketbeat.com - May 1 at 12:38 PMNeurocrine Biosciences Posts Higher 1Q Net Product Salesmarketwatch.com - May 1 at 8:09 AMNeurocrine Biosciences Reports First Quarter 2024 Financial Resultsprnewswire.com - May 1 at 7:00 AMFDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsulesmarkets.businessinsider.com - April 30 at 10:08 PMUPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approvalfinance.yahoo.com - April 30 at 10:08 PMFDA approves Neurocrine Biosciences' Huntington's disease drugreuters.com - April 30 at 5:32 PMNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsulesprnewswire.com - April 30 at 5:12 PMRussell Investments Group Ltd. Sells 8,564 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)marketbeat.com - April 29 at 7:24 AMShort Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Drops By 16.9%americanbankingnews.com - April 28 at 3:14 AMPromising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioningmarkets.businessinsider.com - April 27 at 4:58 AMBuy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Resultsmarkets.businessinsider.com - April 26 at 1:56 PMMaintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developmentsmarkets.businessinsider.com - April 26 at 1:56 PMNew York State Common Retirement Fund Sells 29,456 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)marketbeat.com - April 26 at 7:44 AMAnalysts Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:NBIX)americanbankingnews.com - April 26 at 3:50 AMWells Fargo Upgrades Neurocrine Biosciences (NBIX)msn.com - April 25 at 8:21 PMBrokers Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:NBIX)marketbeat.com - April 25 at 8:31 AMNeurocrine Biosciences (NASDAQ:NBIX) Upgraded by Wells Fargo & Company to Overweightamericanbankingnews.com - April 25 at 7:02 AMNeurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $133.66americanbankingnews.com - April 25 at 6:17 AMNeurocrine launches CAH community website ahead of FDA filingmsn.com - April 25 at 12:18 AMWall Street Analysts Are Neutral on Top Healthcare Picksmarkets.businessinsider.com - April 24 at 2:15 PMNeurocrine Biosciences upgraded at Wells Fargo on pipelinemsn.com - April 24 at 2:15 PMNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Communityfinance.yahoo.com - April 24 at 9:14 AMNeurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwrightmarketbeat.com - April 24 at 8:35 AM3 Red-Hot Biotech Rockets Blasting Off in 2024investorplace.com - April 24 at 8:00 AMJennison Associates LLC Grows Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)marketbeat.com - April 24 at 7:19 AMNeurocrine Biosciences (NASDAQ:NBIX) Lifted to Overweight at Wells Fargo & Companymarketbeat.com - April 24 at 7:08 AMNeurocrine Biosciences (NASDAQ:NBIX) Given Hold Rating at Needham & Company LLCamericanbankingnews.com - April 24 at 4:48 AMNeurocrine Biosciences (NBIX) Scheduled to Post Quarterly Earnings on Wednesdayamericanbankingnews.com - April 24 at 4:12 AMDoes Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?finance.yahoo.com - April 23 at 6:12 PMNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Winfinance.yahoo.com - April 23 at 1:11 PMNeurocrine Biosciences (NASDAQ:NBIX) Receives Hold Rating from Needham & Company LLCmarketbeat.com - April 23 at 8:43 AMNeurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDDmarkets.businessinsider.com - April 23 at 8:09 AM10 Best Performing Biotech ETFs in 2024finance.yahoo.com - April 22 at 12:07 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hussman Strategic Advisors Inc.marketbeat.com - April 22 at 9:17 AM14,857 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Strs Ohiomarketbeat.com - April 21 at 5:25 AMWilliam Blair Weighs in on Neurocrine Biosciences, Inc.'s FY2025 Earnings (NASDAQ:NBIX)marketbeat.com - April 19 at 9:18 AMRoman Butler Fullerton & Co. Buys New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)marketbeat.com - April 18 at 10:41 AM Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Long-Awaited End of America Update (Ad)A 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it. Click here to find out for free. NBIX Media Mentions By Week NBIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.820.36▲Average Medical News Sentiment NBIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼378▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Repligen News Today Exelixis News Today Halozyme Therapeutics News Today Denali Therapeutics News Today Adaptive Biotechnologies News Today Biogen News Today Qiagen News Today Vaxcyte News Today Revolution Medicines News Today BioNTech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing$5,000 Gold?Stansberry ResearchBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
